GREY:ATBPF - Post by User
Post by
WalkOverTheStrton Jun 01, 2020 4:21pm
443 Views
Post# 31098269
Street moving the goal posts / irrational investors
Street moving the goal posts / irrational investors My take (I also posted on Yahoo MB)
The street wants significant low ulcer rates (check as of PH2A), comparable pain mgmt or better (check as of this PH2B study) and now the street is adding that it expects lower liver safety (LTE) than NSAIDs... it is comparable and they want all safety to be lower.
Folks drugs don't work like that, this drug is still based off an NDSAID composition... sounds like moving the goal post to me by the street...
Mgmt didnt do any favors wth a less than clear PR and lack of a scheduled call to disucss the results. I am hopeful the CEO will do this...
IMO this company gets bought in next 6 months for $1B ($2.81 a share)...
""""Acetaminophen use, especially in the post-treatment assessment period, pre-existing liver conditions and concomitant statin use were associated with a majority of the LTE incidents. Accounting for these factors yields clinically significant, temporary LTE incidence rates of 4.5%, 3.2% and 3.3%, respectively, suggesting a liver safety profile for ATB-346 comparable to commonly prescribed NSAIDs and well below that observed with acetaminophen (39% clinically significant LTE incidence rate; National Institutes of Health).